Curriculum vitae
PERSONAL INFORMATION
Philip Van Damme
WORK EXPERIENCE
August 2013–Present
Director of Neuromuscular Reference Center
University Hospital Leuven, (Belgium)
Coordinate diagnostic activities and multidisciplinary care for patients with neuromuscular disorders
August 2006–Present
Adjunct Head of Clinic
University Hospital Leuven, (Belgium)
Neuromuscular disorders
October 2009–Present
Associate Professor
University of Leuven, (Belgium)
Amyotrophic lateral sclerosis (ALS) research, both clinical and fundamental.
EDUCATION AND TRAINING
October 1992–June 1999
Medicine
University of Leuven, (Belgium)
October 2000–September 2004
PhD in Medical Sciences
University of Leuven, (Belgium)
The role of AMPA receptor-mediated excitotoxicity in amyotrophic lateral sclerosis
August 1999–June 2006
Neurology
University of Leuven, (Belgium)
ADDITIONAL INFORMATION
Expertise
Neuromuscular disorders.
Amyotrophic lateral sclerosis.
Frontotemporal dementia.
Publications
2015
1. Dorien Weckhuysen, Maarten Schrooten, Philippe Demaerel, Christine Van Broeckhoven, Thomas
Tousseyn, Gabor G. Kovacs and Philip Van Damme. Genetic Creutzfeldt-Jakob disease mimicking
chronic inflammatory demyelinating polyneuropathy. Neurology Neuroimmunology &
Neuroinflammation 2015: in press. Impact factor . Times cited 0.
2. Steven Boeynaems, Elke Bogaert, Emiel Michiels, Ilse Gijselinck, Anne Sieben, Ana Jovičić, Greet
De Baets, Wendy Scheveneels, Jolien Steyaert, Ivy Cuijt, Kevin J. Verstrepen, Patrick Callaerts,
Frederic Rousseau, Joost Schymkowitz, Marc Cruts, Christine Van Broeckhoven, Philip Van Damme,
Aaron D. Gitler, Wim Robberecht and Ludo Van Den Bosch. Drosophila screen connects nuclear
transport defects to DPR pathology in c9ALS/FTD. Scientific Reports 2015, in press. Impact factor 5,6.
Times cited 0.
3. Bertien Buyse, Philip Van Damme, Catherina Belge, Dries Testelmans. Hypersomnia and REM
sleep abnormalities in adenosine monophosphate deaminase deficiency (AMPD1): more than a
coincidence? J Sleep Research 2015, in press. Impact factor 3,3. Times cited 0.
4. Bart Vrijsen, Bertien Buyse, Catharina Belge, Wim Robberecht, Philip Van Damme, Marc
20/10/15
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 1 / 10
Curriculum vitae
Philip Van Damme
Decramer, Dries Testelmans. Non-invasive ventilation improves sleep in amyotrophic lateral sclerosis:
a prospective polysomnographic study. J Clin Sleep Med e-pub, e-pub,2015. Impact factor 2,8. Times
cited 0.
5. Rose Bruffaerts, Nobuhiro Yuki, Philip Van Damme, Mart Van De Moortele, Magali Wautier, Katrien
Lagrou, Frederik Nevens, Maarten Schrooten. Acute ataxic neuropathy associated with hepatitis E
virus infection. Muscle and Nerve 2015, in press. Impact 2,3. Times cited 0.
6. Koen Van Laere, Guido Wilms, Philip Van Damme. FDG-PET findings in three cases of Mills'
syndrome. Journal of Neurology, Neurosurgery and Psychiatry 2015, in press. Impact factor 5,6.
Times cited 0.
7. Laurens Dobbels, Michael Mahler, Philip Van Damme and Xavier Bossuyt. A 62-year old female
with muscle weakness. Clinical Chemistry 2015, in press. Impact factor 7,8. Times cited 0.
8. Magdolna Kósa, Kitti Brinyiczki, Philip Van Damme, Nathalie Goemans, Károly Hancsák, Luca
Mendler and Erno Zádor. The neonatal sarcoplasmic reticulum Ca2+-ATPase gives a clue to
development and pathology in human muscles. Journal of Muscle Research and Cell Motility 2015,
36(2):195-203. Impact factor 1,9. Times cited 0.
9. Susanna Raitano, Laura Ordovàs, Louis De Muynck, Wenting Guo, Ira Espuny-Camacho, Martine
Geraerts, Satish Khurana, Kim Vanuytsel, Balazs I. Tóth, Thomas Voets, Rik Vandenberghe, Toni
Cathomen, Ludo Van Den Bosch, Pierre Vanderhaeghen, Philip Van Damme*, Catherine M. Verfaillie*
(*contributed equally). Restoration of Progranulin Expression Rescues Cortical Neuron Generation in
Induced Pluripotent Stem Cell Model of Frontotemporal Dementia. Stem Cell Reports 2014, 4(1):1624. Impact factor 5,3. Times cited 0.
2014
10. Louis De Muynck and Philip Van Damme. Peripheral progranulin levels do not reflect brain
progranulin levels. Future Neurology 2014, in press. No impact factor yet. Times cited 0.
11. T. Lengleta, L. Lacomblez, J. L. Abitbol, A. Ludolph, J. S. Mora, W. Robberecht, P. J. Shaw, R. M.
Pruss, V. Cuvier and V. Meininger for the Mitotarget study group (64 authors inclucing P. Van Damme).
A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. European Journal of
Neurology 2014, 21: 529-536. Impact factor 3,9. Times cited 5.
12. Magdalena Zimoń, Esra Battaloğlu, Yesim Parman, Haluk Topaloğlu, Jonathan Baets, Els De
Vriendt, Derek Atkinson, Leonardo Almeida-Souza, Tine Deconinck, Dirk Goossens, Ines Dierick,
Sebahattin Cirak, Philip Van Damme, Mohammad Shboul, Thomas Voit, Lionel Maldergem, Bernard
Dan, Mohammed S. El-Khateeb, Velina Guergueltcheva, Eduardo Lopez-Laso, Gert Matthijs,
Nathalie Goemans, Amira Masri, Stephan Züchner, Vincent Timmerman, Peter De Jonghe & Albena
Jordanova. Unraveling the genetic landscape of autosomal recessive Charcot-Marie-Tooth
neuropathies using a homozygosity mapping approach. Neurogenetics 2014, 16(1):33-42. Impact
factor 2,7. Times cited 0.
13. Shai Carmi, Ken Hui, Ethan Kochav, Xinmin Liu, James Xue, Filan Grady, Saurav Guha, Kinnari
Upadhyay, Dan Ben-Avraham, Semanti Mukherjee, B. Monica Bowen, Vijai Joseph, Marc Cruts, Guy
Froyen, Diether Lambrechts, Stephane Plaisance, Christine Van Broeckhoven, Philip Van Damme,
Herwig Van Marck, Nir Barzilai, Ariel Darvasi, Kenneth Offit, Susan Bressman, Laurie Ozelius, Inga
Peter, Judy Cho, Harry Ostrer, Gil Atzmon, Lorraine Clark, Todd Lencz, and Itsik Pe'er. Whole genome
sequencing of an Ashkenazi Jewish reference panel supports population-targeted personal genomics
and illuminates Jewish and European origins. Nature Communications 2014, 5:4835. Impact factor
10,7. Times cited 1.
14. Frank Diekstra, Vivianna Van Deerlin, John van Swieten, Ammar Al-Chalabi, Albert Ludolph,
Jochen Weishaupt, Orla Hardiman, John Landers, Robert Brown, Jr., Michael van Es, R Pasterkamp,
Max Koppers, Peter Andersen, Karol Estrada, Fernando Rivadeneira, Albert Hofman, André
G.Uitterlinden, Philip Van Damme, Judith Melki, Vincent Meininger, Aleksey Shatunov, Christopher
Shaw, P Leigh, Pamela Shaw, Karen M Morrison, Isabella Fogh, Andriano Chio, Bryan Traynor, David
Czell, Markus Weber, Peter Heutink, Paul de Bakker, Vincenzo Silani, Wim Robberecht, Leonard van
den Berg, Jan Veldink. C9orf72 and UNC13A are shared risk loci for ALS and FTD. Annals of
Neurology 2014, 76(1):120-33. Impact factor 11,9. Times cited 0.
15. Sarah Herdewyn, Carla Cirillo, Ludo Van Den Bosch, Wim Robberecht, Pieter Vanden Berghe
and Philip Van Damme. Prevention of intestinal pseudo-obstruction overcomes sudden death and
reveals progressive neurodegeneration in TDP-43(A315T) mice. Molecular Neurodegeneration 2014,
9(1):24. Impact factor 5,3. Times cited 0.
16. Julie van der Zee, Tim Van Langenhove, Gabor G. Kovacs, Lubina Dillen, William Deschamps,
Sebastiaan Engelborghs, Radoslav Matej, Mathieu Vandenbulcke, Anne Sieben, Bart Dermaut,
Katrien Smets, Philip Van Damme, Céline Merlin,…, Marc Cruts, Christine Van Broeckhoven, on
behalf of the BELNEU consortium and of the EU EOD consortium. Rare mutations in SQSTM1
20/10/15
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 2 / 10
Curriculum vitae
Philip Van Damme
modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathologica 2014, 128(3):397410. Impact factor 9,8. Times cited 2.
17. Anna J. Roy, Peter Van den Bergh, Philip Van Damme, Kris, Doggen, Viviane Van Casteren, On
behalf of the BNMDR Scientific Committee. Early stages of building a rare disease registry, methods
and 2010 data from the Belgian Neuromuscular Disease Registry (BNMDR). Acta Neurologica
Belgica 2014, 115(2):97-104. Impact factor 0,6. Times cited 0.
18. Perry TC van Doormaal, Nicola Ticozzi, Cinzia Gellera, Antonia Ratti, Franco Taroni, Adriano Chiò,
Andrea Calvo, Gabriele Mora, Gabriella Restagno, Bryan J. Traynor, Anna Birve, Robin Lemmens,
M.A. van Es, Christiaan G J Saris, Hylke M Blauw, Paul W J van Vught, Ewout J N Groen, Lucia
Corrado, Letizia Mazzini, Roberto Del Bo, Stefania Corti, Stefan Waibel, Thomas Meyer, Albert C
Ludolph, An Goris, Philip Van Damme, Wim Robberecht, Aleksey Shatunov, Isabella Fogh, Peter M
Andersen, Sandra D’Alfonso, Orla Hardiman, Simon Cronin, Dan Rujescu, Ammar Al-Chalabi, John
E. Landers, Vincenzo Silani, Leonard H van den Berg, Jan H Veldink. Analysis of the KIFAP3 gene in
ALS: a multicenter survival study. Neurobiology of Aging 2014, 35(10):2420.e13-4. Impact factor 4,9.
Times cited 1.
19. Philip Van Damme and Wim Robberecht. Developments in treatments for amyotrophic lateral
sclerosis via intracerebroventricular or intrathecal delivery. Expert Opinion on Investigational Drugs
2014, 23(7):955-63. Impact factor 5,4. Times cited 0.
20. Stefan Lehnert, Julia Costa, Mamade De Carvalho, Janine Kirby,Magdalena Kuzma-Kozakiewicz,
Claudia Morelli, Wim Robberecht, Pamela Shaw, Vincenzo Silani, Petra Steinacker, Hayrettin Tumani,
Philip Van Damme, Albert Ludolph and Markus Otto. Multicentre quality control evaluation of different
biomarker candidates for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and
Frontotemporal Degeneration 2014; Early Online: 1–7. Impact factor 2,6. Times cited 6.
21. Koen Van Laere, Annelies Vanhee, Jolien Verschueren, Liesbeth De Coster, An Driesen, Patrick
Dupont, Wim Robberecht, Philip Van Damme. Value of FDG PET in Amyotrophic Lateral Sclerosis: a
prospective study. JAMA Neurology 2014, 71(5):553-61. Impact factor 7,0. Times cited 3.
22. Isabella Fogh, Antonia Ratti, Cinzia Gellera, Kuang Lin, Cinzia Tiloca, Valentina Moskvina, Lucia
Corrado, Gianni Sorarù, Cristina Cereda, Stefania Corti, Davide Gentilini, Daniela Calini, Barbara
Castellotti, Letizia Mazzini, Giorgia Querin, Stella Gagliardi, Roberto Del Bo, Francesca Luisa Conforti,
Cosenza, Gabriele Siciliano, Maurizio Inghilleri, Francesco Saccà, Paolo Bongioanni, Silvana Penco,
Massimo Corbo, Sandro Sorbi, Massimiliano Filosto, Alessandra Ferlini, Anna Maria Di Blasio,
Stefano Signorini, Aleksey Shatunov, Ashley Jones, Philip Van Damme, Wim Robberecht, Adriano
Chiò, Bryan J Traynor, Judith Melki, Vincent Meininger, Orla Hardiman, Peter M Andersen, Nigel
Leigh, Jonathan D Glass, Jan H Veldink, Michael A van Es, Christopher E Shaw, Michael E Weale,
Cathryn M Lewis, Julie Williams, Robert H Brown, John E Landers, Nicola Ticozzi, Mauro Ceroni,
Elena Pegoraro, Giacomo P Comi, Sandra D’Alfonso, Leonard H van den Berg, Franco Taroni,
Ammar Al-Chalabi, John Powell and Vincenzo Silani, the SLAGEN Consortium and Collaborators. A
genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic
amyotrophic lateral sclerosis. Human Molecular Genetics 2014, 23(8):2220-31. Impact factor 6,7.
Times cited 8.
23. An Goris, Jessica van Setten, Frank Diekstra, Stephan Ripke, Nikolaos A. Patsopoulos, Stephen
J. Sawcer, The International Multiple Sclerosis Genetics Consortium, Michael van Es, The Australia
and New Zealand MS Genetics Consortium, Peter M. Andersen, Judith Melki, Vincent Meininger, Orla
Hardiman, John E. Landers, Robert Brown Jr., Aleksey Shatunov, Nigel Leigh, Ammar Al-Chalabi,
Christopher E. Shaw, Bryan J. Traynor, Adriano Chiò, Gabriella Restagno, Gabriele Mora, Roel A.
Ophoff, Jorge R. Oksenberg, Philip Van Damme, Alastair Compston, Wim Robberecht, Bénédicte
Dubois, Leonard H. van den Berg, Philip L. De Jager, Jan H. Veldink, Paul I.W. de Bakker. No
evidence for shared genetic basis of common variants in multiple sclerosis and amyotrophic lateral
sclerosis. Human Molecular Genetics 2014, 23(7): 1916-1922. Impact factor 6,7. Times cited 1.
2013
24. Staats KA, Schönefeldt S, Van Rillaer M, Van Hoecke A, Van Damme P, Robberecht W, Liston A,
Van Den Bosch L. Beta-2 microglobulin is important for disease progression in a murine model for
amyotrophic lateral sclerosis. Front Cell Neurosci 2013, 10;7:249. Impact factor 4,2. Times cited 4.
25. Mertens J, Stüber K, Wunderlich P, Ladewig J, Kesavan JC, Vandenberghe R, Vandenbulcke M,
Van Damme P, Walter J, Brüstle O, Koch P. APP Processing in Human Pluripotent Stem Cell-Derived
Neurons Is Resistant to NSAID-Based γ-Secretase Modulation. Stem Cell Reports 2013, 1(6):491-8.
Impact factor not known yet . Times cited 13.
26. Kim Staats, Sara Hernandez, Susann Schönefeldt, André Bento-Abreu, James Dooley, Philip Van
Damme, Adrian Liston, Wim Robberecht and Ludo Van Den Bosch. Rapamycin increases survival in
ALS mice lacking mature lymphocytes. Molecular Neurodegeneration 2013, 8(1):31. Impact factor
5,3. Times cited 4.
20/10/15
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 3 / 10
Curriculum vitae
Philip Van Damme
27. Hui Zhao, Valérie Race, Gert Matthijs, Peter De Jonghe, Wim Robberecht, Diether Lambrechts,
and Philip Van Damme. Exome sequencing reveals HINT1 mutations as a cause of distal hereditary
motor neuropathy. European Journal of Human Genetics 2013, 22(6):847-50. Impact factor 4,2. Times
cited 4.
28. Kim Staats, Lawrence Van Helleputte, Ashley Jones, André Bento-Abreu, Annelies Van Hoecke,
Aleksey Shatunov, Claire L Simpson, Robin Lemmens, Tom Jaspers, Kiyoko Fukami, Yoshikazu
Nakamura, Robert Brown Jr, Philip Van Damme, Adrian Liston, Wim Robberecht, Ammar Al-Chalabi,
Ludo Van Den Bosch. Genetic ablation of phospholipase C delta 1 increases survival in SOD1G93A
mice, Neurobiology of Disease 2013, 60:11-17. Impact factor 5,2. Times cited 3.
29. Sarah Debray, Valérie Race, Veerle Crabbé, Sarah Herdewyn, Gert Matthijs, An Goris, Bénédicte
Dubois, Vincent Thijs, Wim Robberecht and Philip Van Damme. Frequency of C9orf72 repeat
expansions in ALS: a Belgian cohort study. Neurobiology of aging 2013, 34(12):2890.e7-2890.e12.
Impact factor 4,9. Times cited 6.
30. Philip Van Damme and Wim Robberecht. Clinical implications of recent breakthroughs in
amyotrophic lateral sclerosis. Current Opinion in Neurology 2013, 26(5):466-72. Impact factor 5,7.
Times cited 8.
31. Louis De Muynck, Sarah Herdewyn, Sander Beel, Wendy Scheveneels, Ludo Van Den Bosch,
Wim Robberecht and Philip Van Damme. The neurotrophic properties of progranulin depend on the
granulin E domain but do not require sortilin binding. Neurobiology of aging 2013, 34(11):2541-2547.
Impact factor 4,9. Times cited 9.
32. Sarah Herdewyn, Louis De Muynck, Ludo Van Den Bosch, Wim Robberecht, Philip Van Damme.
Progranulin does not affect motor neuron degeneration in mutant SOD1 mice and rats. Neurobiology
of Aging 2013, 34(10):2302-2303. Impact factor 4,9. Times cited 1.
33. Thomas Philips, Andre Bento-Abreu, Annelies Nonneman, Wanda Haeck, Kim Staats, Veerle
Geelen, Nicole Hersmus, Benno Küsters, Ludo Van Den Bosch, Philip Van Damme, William D.
Richardson and Wim Robberecht. Oligodendrocyte dysfunction in the pathogenesis of amyotrophic
lateral sclerosis. Brain 2013, 136:471-82. Impact factor 10,2. Times cited 30.
34. Taes Ines, Timmers Mieke, Nicole Hersmus, André Abreu Bento, Ludo Van Den Bosch, Philip Van
Damme, Johan Auwerx, Tso-Pang Yao, Robberecht Wim. Hdac6 deletion delays disease progression
in SOD1G93A mouse model of ALS. Human Molecular Genetics 2013, 22(9):1783-90. Impact factor
6,7. Times cited 18.
35. Christopher Gieraerts, Philippe Demaerel, Philip Van Damme, Guido Wilms. MELAS syndrome
mimicking herpes simplex encephalitis on imaging studies. Journal of Computer Assisted Tomography
2013, 37(2):279-81. Impact factor 1,6. Times cited 1.
36. Bart Vrijsen, Dries Testelmans, Catharina Belge, Wim Robberecht, Philip Van Damme and Bertien
Buyse. Non-invasive ventilation in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis 2013,
14(2):85-95. Impact factor 2,6. Times cited 3.
37. Bradley N Smith, Stephen Newhouse, Aleksey Shatunov, Caroline Vance, Simon Topp, Lauren
Johnson, Jack Miller, Younbok Lee, Claire Troakes, Kirsten M Scott, Ashley Jones, Ian Gray, Jamie
Wright, Tibor Hortoba´gyi, Safa Al-Sarraj, Boris Rogelj, John Powell, Michelle Lupton, Simon
Lovestone, Peter C Sapp, Markus Weber, Peter J Nestor, Helenius J Schelhaas, Anneloor ALM ten
Asbroek, Vincenzo Silani, Cinzia Gellera, Franco Taroni, Nicola Ticozzi, Leonard Van den Berg, Jan
Veldink, Phillip Van Damme, Wim Robberecht, Pamela J Shaw, Janine Kirby, Hardev Pall, Karen E
Morrison, Alex Morris, Jacqueline de Belleroche, JMB Vianney de Jong, Frank Baas, Peter M
Andersen, John Landers, Robert H Brown Jr, Michael E Weale, Ammar Al-Chalabi and Christopher E
Shaw. The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a
single founder. European Journal of Human Genetics 2013,21(1):102-108. Impact factor 4,2. Times
cited 63.
38. The ALSGEN consortium. Age of onset of amyotrophic lateral sclerosis is modulated by a locus
on 1p34.1. Neurobiology of aging 2013,34(1): 357 e7-357 e19. Impact factor 4,9.
39. Wouter van Rheenen, Frank P. Diekstra, Kevin Kenna, Russell McLaughlin, Aleksey Shatunov,
David Czell, Paul W.J. van Vught, Philip Van Damme, Stefan Waibel, H. Jurgen Schelhaas, Anneke J.
van der Kooi, Marianne de Visser, Markus Weber, Wim Robberecht, Orla Hardiman, Ammar AlChalabi, Peter M. Andersen, Albert C. Ludolph, Jan H. Veldink, Leonard H. van den Berg. H63D
polymorphism in HFE is not associated with amyotrophic lateral sclerosis. Neurobiology of aging
2013,34(5):1517.e5-7. Impact factor 4,9. Times cited 10.
2012
40. Kim Staats, Elke Bogaert, Nicole Hersmus, Tom Jaspers, Tomas Luyten, Geert Bultynck, Jan B
Parys, Chihiro Hisatsune, Katsuhiko Mikoshiba, Philip Van Damme, Wim Robberecht, Ludo Van Den
Bosch. Neuronal overexpression of IP3 receptor 2 is detrimental in mutant SOD1 mice. Biochemical
20/10/15
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 4 / 10
Curriculum vitae
Philip Van Damme
and Biophysical Research Communications 2012, 429(3-4):210-213. Impact factor 2,4. Times cited 2.
41. Annelies Van Hoecke, Lies Schoonaert, Robin Lemmens, Mieke Timmers, Kim A Staats, Angela
S Laird, Elke Peeters, Thomas Philips, An Goris, Benedicte Dubois, Peter Andersen, Ammar AlChalabi, Vincent Thijs, Ann M Turnley, Paul W van Vught, Jan H Veldink, Ludo Van Den Bosch,
Paloma Gonzalez-Perez, Philip Van Damme, Robert H Brown Jr, Leonard H van den Berg, Wim
Robberecht. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in
humans. Nature Medicine 2012, 18(9):1418-22. Impact factor 24,3. Times cited 73.
42. Magdalena Zimoń, Jonathan Baets, Leonardo Almeida-Souza, Els De Vriendt, Jelena
Nikodinovic, Yesim Parman, Esra Battaloğlu, Zeliha Matur, Velina Guergueltcheva, Ivailo Tournev,
Michaela Auer-Grumabach, Peter De Rijk, Britt-Sabina Petersen, Thomas Müller, Erik Fransen, Philip
Van Damme, Wolfgang N. Löscher, Nina Barišić, Zoran Mitrovic, Stefano C. Previtali, Haluk Topaloğlu,
Günther Bernert, Ana Beleza-Meireles, Slobodanka Todorovic , Dusanka Savic- Pavicevic, Boryana
Ishpekova, Silvia Lechner, Kristien Peeters, Tinne Ooms, Angelika F. Hahn, Stephan Züchner, Vincent
Timmerman, Patrick Van Dijck, Vedrana Milic Rasic, Andreas R. Janecke, Peter De Jonghe & Albena
Jordanova. Loss of function mutations in HINT1 are a major cause of peripheral neuropathy with
neuromyotonia. Nature Genetics 2012, 44(10):1080-1083. Impact factor 35,2. Times cited 24.
43. K.A. Staats, M. Van Rillaer, W. Scheveneels, C. Van Heijningen, R. Verbesselt, P. Van Damme, W.
Robberecht and L. Van Den Bosch. Dantrolene is neuroprotective in vitro, but does not affect survival
in SOD1G93A mice. Neuroscience 2012, 8(220):26-31. Impact factor 3,1. Times cited 5.
44. Hylke M. Blauw, Wouter van Rheenen, Max Koppers, Philip Van Damme, Stefan Waibel, Robin
Lemmens, Paul W. J. van Vught, Thomas Meyer, Claudia Schulte, Thomas Gasser, Edwin Cuppen,
R. Jeroen Pasterkamp, Wim Robberecht, Albert C. Ludolph, Jan H. Veldink, Leonard H. van den
Berg. NIPA1 polyalanine repeat expansions are associated with amyotrophic lateral sclerosis. Human
Molecular Genetics 2012, 21(11):2497-2502. Impact factor 7,8. Times cited 11.
45. Sarah Herdewyn, Hui Zhao, Mathieu Moisse, Valérie Race, Gert Matthijs, Joke Reumers, Benno
Kusters, Helenius J. Schelhaas, Leonard H. van den Berg, An Goris, Wim Robberecht, Diether
Lambrechts and Philip Van Damme. Whole-genome sequencing reveals a coding non-pathogenic
variant tagging a non-coding pathogenic hexanucleotide repeat expansion in C9orf72 as cause of
amyotrophic lateral sclerosis. Human Molecular Genetics 2012, 21(11):2412-2419. Impact factor 7,8.
Times cited 14.
46. Maarten Schrooten, Wim Robberecht and Philip Van Damme. From El Escorial to Awaji: where do
we go next with the ALS criteria? Neurodegenerative Disease Management 2012, 2(1):135-140.
Impact factor?. Times cited 0.
47. The EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis: Peter M.
Andersen, Sharon Abrahams, Gian D. Borasio, Mamede de Carvalho, Adriano Chio, Philip Van
Damme, Orla Hardiman, Katja Kollewe, Karen E. Morrison, Susanne Petri, Pierre-Francois Pradat,
Vincenzo Silani, Barbara Tomik, Maria Wasner, and Markus Weber. EFNS guidelines on the Clinical
Management of Amyotrophic Lateral Sclerosis (MALS) - revised report of an EFNS task force.
European Journal of Neurology 2012, 19(3):360-375. Impact factor 4,2. Times cited 95.
48. Elke Bogaert, An Goris, Philip Van Damme, Veerle Geelen, Robin Lemmens, Michael van Es,
Leonard H. van den Bergh, Kristel Sleegers, Nathalie Verpoorten, Vincent Timmerman, Peter De
Jonghe, Christine Van Broeckhoven, Brian Traynor, John E. Landers, Robert H. Brown Jr., Ammar AlChalabi, Christopher E. Shaw, Anna Birve, Peter M. Andersen, Agnieszka Slowik, Barbara Tomik,
Judith Melki, Wim Robberecht and Ludo Van Den Bosch. Polymorphisms in the GluR2 gene are not
associated with amyotrophic lateral sclerosis. Neurobiology of aging 2012;33(2):418-20. Impact factor
6,2. Times cited 2.
49. Frank P. Diekstra, Paul W.J. van Vught, Wouter van Rheenen, Max Koppers, R. Jeroen
Pasterkamp, Michael A. van Es, H. Jurgen Schelhaas, Marianne de Visser, Wim Robberecht, Philip
Van Damme, Peter M. Andersen, Leonard H. van den Berg, and Jan H. Veldink. UNC13A is a
modifier of survival in amyotrophic lateral sclerosis. Neurobiology of Aging, 2012, 33(3):630.e3-8.
Impact factor 6,2. Times cited 19.
2011
50. Michael A van Es, Helenius J Schelhaas, Paul WJ van Vught, Nicola Ticozzi, Peter M Andersen,
Ewout JN Groen, Claudia Schulte, Hylke M Blauw, Max Koppers, Frank P Diekstra, Katsumi Fumoto,
Ashley Lyn LeClerc, Pamela Keagle, Bastiaan R Bloem, Hans Scheffer, Bart FL van Nuenen, Marka
van Blitterswijk, Wouter van Rheenen, Anne-Marie Wills, Patrick P Lowe, Guo-fu Hu, Wenhao Yu,
Hiroko Kishikawa, David Wu, Rebecca D Folkerth, Claudio Mariani, Stefano Goldwurm, Gianni
Pezzoli, Philip Van Damme, Robin Lemmens, Caroline Dahlberg, Anna Birve, Rubén FernándezSantiago, Stefan Waibel, Christine Klein, Markus Weber, Anneke J van der Kooi, Marianne de Visser,
Dagmar Verbaan, Jacobus J van Hilten, Peter Heutink , Eric AM Hennekam, Edwin Cuppen, Daniela
Berg, Robert H. Brown Jr, Vincenzo Silani, Thomas Gasser, Albert C Ludolph, Wim Robberecht, Roel
20/10/15
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 5 / 10
Curriculum vitae
Philip Van Damme
A Ophoff, Jan H Veldink, R Jeroen Pasterkamp, Paul IW de Bakker, John E Landers, Bart P van de
Warrenburg, Leonard H van den Berg. Angiogenin variants in Parkinson’s disease and amyotrophic
lateral sclerosis. Annals of Neurology 2011, 70(6): 964-973. Impact factor 11,1. Times cited 58.
51. Louis De Muynck and Philip Van Damme. The cellular effects of progranulin in health and disease.
The Journal of Molecular Neuroscience 2011, 45(3):549-560. Impact factor 2,5. Times cited 22.
52. Constantin d’Ydewalle, Jyothsna Krishnan, Driss M. Chiheb, Philip Van Damme, Joy Irobi, Pieter
Vanden Berghe, Vincent Timmerman, Wim Robberecht and Ludo Van Den Bosch. HDAC6 inhibitors
reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease.
Nature Medicine 2011, 17(8):968-74. Impact factor 22,5. Times cited 101.
53. Lujia Zhou, Nathalie Brouwers, Iryna Belinova, Annelies Vandersteen, Marc Mercken, Koen Van
Laere, Philip Van Damme, David Demedts, Fred Van Leuven, Kristel Sleegers, Kerensa Broersen,
Christine Van Broeckhoven, Rik Vandenberghe, Bart De Strooper. Amyloid Precursor Protein
mutation E682K at the alternative β-secretase cleavage β'- site increases Aβ generation. EMBO Mol
Med 2011, 3(5):291-302. Impact factor 10,3. Times cited 24.
54. Evelyne Coussee, Elke Bogaert, Patrick De Smet, Liesbeth Faes, Petra D’hooge, Iris Elens, Philip
Van Damme, Wim Robberecht, Peter Willems, Werner Koopman, Ludo Van Den Bosch and Geert
Callewaert. Mutant SOD1 impairs mitochondrial calcium uptake and ATP synthesis in intact neuronal
cells. Cell Calcium 2011, 49(4):217-225. Impact factor 3,8. Times cited 11.
55. Martin R Turner, Julian Grosskreutz, Jan Kassubek, Sharon Abrahams, Federica Agosta, Michael
Benatar, Massimo Filippi, Laura H Goldstein, Martijn van den Heuvel, Sanjay Kalra, Dorothée Lulé,
Bahram Mohammadi, Nazem Atassi, Peter Bede, Habib Benali, Christian Enzinger, Christian Gaser,
Laura Jelsone-Swain, Hans-Peter Müller, Richard W. Orrell, Pierre-François Pradat, Johannes Prudlo,
Stefan Ropele, Rakesh Sharma, Vincenzo Silani, Andrew Simmons, Stephen Smith, Stefan Teipel,
Ahmed Toosy, Stella Tsermentseli, Philip Van Damme, Esther Verstraete, Robert Welsh, Matthias
Wittstock. Towards a neuroimaging biomarker in amyotrophic lateral sclerosis. The Lancet Neurology
2011, 10(5):400-403. Impact factor 23,5. Times cited 71.
56. Philip Van Damme, Jan Herman Veldink, Marka van Blitterwijk, Anniek Corveleyn, Paul van Vught,
Vincent N. Thijs, Bénédicte Dubois, Gert Matthijs, Leonard H. van den Berg, and Wim Robberecht.
Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2.
Neurology 2011, 76:2066-2072. Impact factor 8,3. Times cited 76.
57. Maarten Schrooten, Charlotte Smetcoren, Wim Robberecht, and Philip Van Damme. Benefit of
the Awaji diagnostic algorithm for ALS, a prospective study. Annals of Neurology 2011, 70(1):79-83.
Impact factor 11,1. Times cited 33.
2010
58. Angela Laird, Annelies Van Hoecke, Louis De Muynck, Mieke Timmers, Ludo Van Den Bosch,
Philip Van Damme, Wim Robberecht. Progranulin is neurotrophic in vivo and protects against a
mutant TDP-43 induced axonopathy. PLoS ONE 2010, 5(10):e13368. Impact factor 4,4. Times cited
39.
59. Thomas Philips, Louis De Muynck, Hoai Thi Nguyen, Bea Weynants, Peter Vanacker, Joke
Dhondt, Kristel Sleegers, Helenius J. Schelhaas, Marcel Verbeek, Rik Vandenberghe, Raf Sciot,
Christine Van Broeckhoven, Diether Lambrechts, Fred Van Leuven, Ludo Van Den Bosch, Wim
Robberecht and Philip Van Damme. Microglial upregulation of progranulin as marker of motor neuron
degeneration. J Neuropathol Exp Neurol 2010, 69(12):1191-1200. Impact factor 4,2. Times cited 27.
60. Aleksey Shatunov, Kin Mok, Stephen Newhouse, Michael E Weale, Bradley Smith, Caroline
Vance, Lauren Johnson, Jan Veldink, Michael van Es, Leonard van den Berg, Wim Robberecht, Philip
Van Damme, Orla Hardiman, Anne E Farmer, Cathryn M Lewis, Wai-Ling Butler, Olubunmi Abel,
Peter M Andersen, Isabella Fogh, Vincenzo Silani, Adriano Chio, Bryan J Traynor, Judith Melki,
Vincent Meininger, John E Landers, Peter McGuffin, Jonathan D Glass, Hardev Pall, P Nigel Leigh,
John Hardy, Robert H Brown, John F Powell, Richard W Orrell, Karen E Morrison, Pamela J Shaw,
Christopher E Shaw, Ammar Al-Chalabi. Chromosome 9p21 in sporadic amyotrophic lateral sclerosis
in the UK and seven other countries: a genome-wide association study. The Lancet Neurology 2010,
9(10):986-994. Impact factor 21,7. Times cited 126.
61. André Bento-Abreu, Philip Van Damme, Ludo Van Den Bosch, Wim Robberecht. The
neurobiology of amyotrophic lateral sclerosis. European Journal of Neuroscience 2010, 31(12):22472265. Impact factor 3,7. Times cited 47.
62. Vincent Thijs, Robin Lemmens, Christophe Schoofs, Astrid Görner, Philip Van Damme, Maarten
Schrooten, Philippe Demaerel. Microbleeds and risk of recurrent stroke. Stroke 2010, 41(9):20052009. Impact factor 5,8. Times cited 48.
63. Michel Delforge, Joan Bladé, Meletios A Dimopoulos, Thierry Facon, Martin Kropff, Heinz Ludwig,
Antonio Palumbo, Philip Van Damme, Jesús F San-Miguel, Pieter Sonneveld. Treatment-related
20/10/15
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 6 / 10
Curriculum vitae
Philip Van Damme
peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncology 2010,
11(11):1086-95. Impact factor 17,8. Times cited 84.
64. Jonathan Baets, Tine Deconinck, Katrien Smets, Dirk Goossens, Peter Van Den Berg, Karin
Dahan, Eric Schmedding, Patrick Santens, Vedrana Milic Rasic, Philip Van Damme, Wim Robberecht,
Linda De Meirleir, Boudewijn Michielsens, Albena Jordanova and Peter De Jonghe. Mutations in
SACS cause atypical and late onset forms of autosomal recessive spastic ataxia of CharlevoixSaguenay. Neurology 2010, 75:1181-1188. Impact factor 8,0. Times cited 33.
65. Ines Taes, An Goris, Robin Lemmens, Michael van Es, Leonard Van den Berg, Adriano Chio,
Bryan J Traynor, Anna Birve, Peter Andersen, Agnieszka Slowik, Barbara Tomik, Robert H Brown Jr,
Christopher E Shaw, Ammar Al-Chalabi, Steven Boonen, Ludo Van Den Bosch, Benedicte Dubois,
Philip Van Damme, Wim Robberecht. Tau levels do not contribute to human ALS or motor neuron
degeneration in the SOD1G93A mouse model. Neurology 2010, 74(21):1687-1693. Impact factor 8,0.
Times cited 10.
66. Maarten Dewil, Wim Robberecht and Philip Van Damme. An unusual presentation of GuillainBarré syndrome associated with monospecific anti-GD1b antibodies. Journal of Neurology,
Neurosurgery and Psychiatry 2009, 81(5):587-588. Impact factor 4,8. Times cited 1.
67. Jun Wang, Philip Van Damme, Carlos Cruchaga, Michael A. Gitcho, Jose Manuel Vidal, Manuel
Seijo-Martínez, Lei Wang, Jane Y. Wu, Wim Robberecht and Alison Goate. Pathogenic Cysteine
Mutations Affect Progranulin Function and Production of Mature Granulins. Journal of Neurochemistry
2010, 112:1305-1315. Impact factor 4,3. Times cited 28.
68. Elke Bogaert, Philip Van Damme, Koen Poesen, Joke Dhondt, Nicole Hersmus, Dora Kiraly,
Wendy Scheveneels, Wim Robberecht and Ludo Van Den Bosch. VEGF protects motor neurons
against excitotoxicity by upregulation of GluR2. Neurobiol Aging 2010, 31(12):2185-91. Impact factor
6,6. Times cited 52.
69. Philip Van Damme, An Goris, Valérie Race, Nicole Hersmus, Bénédicte Dubois, Ludo Van Den
Bosch, Gert Matthijs and Wim Robberecht. The occurrence of mutations in FUS in a Belgian cohort of
familial ALS patients. European Journal of Neurology 2010, 17(5):754-756. Impact factor 3,8. Times
cited 40.
2009
70. Philip Van Damme and Wim Robberecht. Recent advances in motor neuron disease. Current
opinion in neurology 2009, 22(5):486-92. Impact factor 5,4. Times cited 52.
71. Philip Van Damme, Werner Spileers, Philippe Demaerel and Wim Robberecht. Autosomal
Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS). Neurology 2009, 72(20):1790. Impact
factor 8,2. Times cited 7.
72. Greet Hermans, Maarten Schrooten, Philip Van Damme, Noor Berends, Bernard Bouckaert,
Wouter De Vooght, Wim Robberecht, Greet Van den Berghe. Benefits of intensive insulin therapy on
neuromuscular complications in routine daily critical care practice: a retrospective study. Critical care
2009, 13(1):R5. Impact factor 4,9. Times cited 26.
73. Kristel Sleegers, Nathalie Brouwers, Philip Van Damme, Sebastiaan Engelborghs, Ilse Gijselinck,
Julie van der Zee, Karin Peeters, Maria Mattheijssens, Marc Cruts, Rik Vandenberghe, Peter P De
Deyn, Wim Robberecht and Christine Van Broeckhoven. A serum biomarker for progranulinassociated frontotemporal lobar degeneration. Annals of Neurology 2009, 65(5):603-9. Impact factor
9,3. Times cited 93.
74. Robin Lemmens, Valerie Race, Nicole Hersmus,Gert Matthijs, Ludo Van Den Bosch, Philip Van
Damme, Bénédicte Dubois, Steven Boonen, An Goris, Wim Robberecht. TDP-43 M311V Mutation in
Familial Amyotrophic Lateral Sclerosis. Journal of Neurology Neurosurgery and Psychiatry 2009,
80(3):354-5. Impact factor 4,9. Times cited 39.
2008
75. Koen Poesen, Diether Lambrechts, Philip Van Damme, Joke Dhondt, Florian Bender, Nicolas
Frank, Elke Bogaert, Bart Claes, Line Heylen, An Verheyen, Katrien Raes, Marc Tjwa, Ulf Eriksson,
Masabumi Shibuya, Rony Nuydens, Ludo Van Den Bosch, Theo Meert, Rudi D'Hooge, Michael
Sendtner, Wim Robberecht, and Peter Carmeliet. Novel Role for VEGF-Receptor-1 and its Ligand
VEGF-B in Motor Neuron Degeneration. Journal of Neuroscience 2008, 28:10451-10459. Impact
factor 7,5. Times cited 66.
76. Maarten Schrooten, Wouter De Vooght, Sarah Weckhuysen, Wim Van Paesschen and Philip Van
Damme. Normalization of 14-3-3 in CJD. Acta Neurologica Belgica 2008, 108:64-66. Impact factor
0,8. Times cited 5.
77. Philip Van Damme, Annelies Van Hoecke, Diether Lambrechts, Peter Vanacker, Elke Bogaert,
John van Swieten, Peter Carmeliet, Ludo Van Den Bosch and Wim Robberecht. Progranulin functions
20/10/15
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 7 / 10
Curriculum vitae
Philip Van Damme
as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. The Journal of
Cell Biology 2008, 181(1):37-41. Impact factor 9,1. Times cited 159.
78. K. Sleegers, N. Brouwers, S. Maurer-Stroh, M.A. van Es, P. Van Damme, P.W.J van Vught, J. van
der Zee, S. Serneels, T. De Pooter, M. Van den Broeck, M. Cruts, J. Schymkowitz, P. De Jonghe, F.
Rousseau, L.H. van den Berg, W. Robberecht, C. Van Broeckhoven. Progranulin genetic variability
contributes to amyotrophic lateral sclerosis. Neurology 2008, 71(4):253-259. Impact factor 7,0. Times
cited 103.
2007
79. Philip Van Damme, Elke Bogaert, Maarten Dewil, Nicole Hersmus, Dora Kiraly, Wendy
Scheveneels, Ilse Bockx, Dries Braeken, Nathalie Verpoorten, Kristien Verhoeven, Vincent
Timmerman, Paul Herijgers, Geert Callewaert, Peter Carmeliet, Ludo Van Den Bosch, Wim
Robberecht. From the cover: Astrocytes regulate GluR2 expression in motor neurons and their
vulnerability to excitotoxicity. Proceedings of the National Academy of Sciences USA 2007,
104(37):14825-14830. Impact factor 9,6. Times cited 118.
80. Julian Grosskreutz, Kristen Haastert, Maarten Dewil, Philip Van Damme, Geert Callewaert, Wim
Robberecht, Reinhard Dengler and Ludo Van Den Bosch. Role of mitochondria in kainate-induced
fast Ca2+ transients in cultured spinal motor neurons. Cell Calcium 2007, 42(1):59-69. Impact factor
4,3. Times cited 34.
81. Maria Andries, Philip Van Damme, Wim Robberecht and Ludo Van Den Bosch. Ivermectin inhibits
AMPA receptor-mediated excitotoxicity in cultured motor neurons and extends the life span of a
transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2007, 25(1):8-16. Impact
factor 4,4. Times cited 22.
2006
82. Van Den Bosch L., Van Damme P., Bogaert E. and Robberecht W. The role of excitotoxicity in the
pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta 2006, 1762(11-12):1068-82.
Impact factor 3,3. Times cited 222.
83. Elke Bogaert, Philip Van Damme, Ludo Van Den Bosch and Wim Robberecht. VEGF in
amyotrophic lateral sclerosis and other neurodegenerative diseases. Muscle and Nerve 2006,
34:391–405. Impact factor 2,5. Times cited 36.
2005
84. P. Van Damme, M. Dewil, W. Robberecht and L. Van Den Bosch. Excitotoxicity and amyotrophic
lateral sclerosis. Neurodegenerative Dis 2005, 2(3-4):147-159. Impact factor 3,5. Times cited 94.
85. Philip Van Damme, Dries Braeken, Geert Callewaert, Wim Robberecht and Ludo Van Den Bosch.
GluR2 deficiency accelerates motor neuron degeneration in a mouse model of amyotrophic lateral
sclerosis. J Neuropathol Exp Neurol 2005, 64(7): 605-612. Impact factor 4,5. Times cited 80.
86. Erik Strokebaum, Diether Lambrechts, Mieke Dewerchin, Maria-Paz Moreno-Murciano, Saskia
Appelmans, Hideyasu Oh, Philip Van Damme, Bart Rutten, Wing Yan Man, Maria De Mol, Sabine
Wyns, David Manka, Kristel Vermeulen, Ludo Van Den Bosch, Nico Mertens, Christoph Schmitz, Wim
Robberecht, Edward M Conway, Désiré Collen, Lieve Moons and Peter Carmeliet. Treatment of
motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nature
Neurosci 2005, 8(1):85-92. Impact factor 15,5. Times cited 429.
2004
87. Chabwine J., Van Damme P., Eggermont J., De Smedt H., Missiaen L., Van Den Bosch L., Parys
J., Robberecht W., Callewaert G. Long-lasting changes in GABA responsiveness in cultured neurons.
Neurosci Lett 2004, 365:69-72. Impact factor 2,0. Times cited 6.
2003
88. Van Damme P., Callewaert G., Eggermont J., Robberecht W., and Van Den Bosch L. Chloride
influx aggravates Ca2+-dependent AMPA receptor-mediated motoneuron death. J Neurosci 2003,
23(12):4942-50. Impact factor 8,3. Times cited 42.
89. Van Damme P., Leyssen M., Callewaert G., Robberecht W., and Van Den Bosch L. The AMPA
receptor antagonist NBQX prolongs survival in a transgenic mouse model of amyotrophic lateral
sclerosis. Neurosci Lett 2003, 343(2):81-84. Impact factor 2,0. Times cited 92.
2002
90. Vleminckx V., Van Damme P., Goffin K., Delye H., Van Den Bosch L., and Robberecht W.
Upregulation of HSP27 in a transgenic model of ALS. J Neuropathol Exp Neurol 2002, 61(11):968974. Impact factor 5,0. Times cited 82.
91. Van Damme P., Van Den Bosch L., Van Houtte E., Callewaert G., and Robberecht W. GluR2dependent properties of AMPA receptors determine the selective vulnerability of motor neurons to
20/10/15
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 8 / 10
Curriculum vitae
Philip Van Damme
excitotoxicity. J Neurophysiol 2002, 88:1279-1287. Impact factor 3,7. Times cited 104.
92. Van Damme P., Van Den Bosch L., Van Houtte E., Eggermont J., Callewaert G., and Robberecht
W. Na+ entry through AMPA receptors results in voltage-gated K+ channel blockade in cultured rat
spinal cord motoneurons. J Neurophysiol 2002, 88:965-972. Impact factor 3,7. Times cited 15.
93. Van Den Bosch L., Van Damme P., Vleminckx V., Van Houtte E., Lemmens G., Missiaen L.,
Callewaert G., Robberecht W. An alpha-mercaptoacrylic acid derivative (PD150606) inhibits selective
motor neuron death via inhibition of kainate-induced Ca2+ influx and not via calpain inhibition.
Neuropharmacology 2002, 42(5):706-713. Impact factor 3,4. Times cited 48.
Projects
Projects:
- Overlap between ALS and FTD
- FDG-PET in ALS
- Genetics of ALS and dHMN
- The role of progranulin in neurodegeneration
- The role of C9orf72 in neurodegeneration
Memberships
Memberships:
- Society for Neuroscience
- American Academy of Neurology
- Belgian Neurological Society
- Flemish Neurological Society
Scientific Awards:
2011: Price of the ‘Baron Simonart Foundation’ for research in clinical pharmacology, Belgium.
2009: The ‘Schamelhout-Koettlitz’ Prize from the Royal Academy of Medicine, Belgium.
2007: Prize of the Horlait-Dapsens Foundation.
2006: Prize for the best poster presentation at Neurobelgium, Genval.
2006: Prize of the Willy et Marcy de Vooght Foundation.
2006: Pfizer Educational Grant, June 21th.
2004: Prize Eli Lilly-V.V.Z. for Neurology. The role of chloride ions in AMPA receptor-mediated motor
neuron death.
Other Relevant Information
Experience with clinical trials:
- Phase II: Novartis CBAF312X2205: A multi-centre, double-blind, placebo-controlled, proof of concept
study to evaluate the efficacy and tolerability of BAF312 in patients with polymyositis ( October 2014present).
- Phase II: Novartis CBAF312X2206: A double-blind, randomized, placebo-controlled study to
evaluate safety, tolerability, efficacy and preliminary dose-response of BAF312 in patients with active
dermatomyositis ( October 2014-present).
- Phase III: ECU-MG-301: A randomized, double-blind, placebo-controlled, multi-center study to
evaluate the safety and efficacy of Eculizumab in subjects with refractory generalized myasthenia
gravis (September 2014-present, principal investigator).
- Phase I: Newron-Sweden sNN0029-003: A phase I, randomised, double-blind, placebo-controlled
study in patients with amyotrophic lateral sclerosis to further assess the safety and tolerability of
intracerebroventricular administration of sNN0029 infusion solution (August 2014- present,
coordinating principal investigator).
- Phase I: Sanofi NeoGAA (TDR12857): An open-label, multicenter, multinational, ascending dose
study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of
repeated biweekly infusions of neoGAA in naïve and alfa-glucosidase treated late-onset Pompe
disease patients (September 2013-present, principal investigator).
- Phase II/III: Novartis FTY720/Fingolimod: A double-blind, randomized, multicenter, placebocontrolled, parallel-group study to evaluated the efficacy and safety of fingolimod 0.5 mg administered
orally once daily versus placebo in patients with chronic inflammatory demyelinating
20/10/15
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 9 / 10
Curriculum vitae
Philip Van Damme
polyradiculoneuropathy (CIDP) (May 2013- present, co-investigator).
- Phase III: GSK NOG112264 study: A Phase II Study of Ozanezumab (GSK1223249) versus
placebo in the treatment of Amyotrophic Lateral Sclerosis (ALS) (December 2012-present, coinvestigator).
- Phase III: CSL Behring PATH study (IgPro 20): Randomized, multicenter, double-blind, placebocontrolled, parallel-group phase III study to investigate the efficacy, safety, and tolerability of 2 different
doses of IgPro20 (subcutaneous immunoglobulin) for the treatment of chronic inflammatory
demyelinating polyneuropathy (CIDP)- the PATH study (November 2012- present, principal
investigator).
- Phase III: Biogen Idec Study 223AS302 - A Randomized, Double-Blind, Placebo-Controlled, MultiCenter Study of the Safety and Efficacy of Dexpramipexole in Subjects with Amyotrophic Lateral
Sclerosis (June 2011-January 2013, co-investigator).
- Phase IV: CSL Behring Study Privigen (IgPro 10): A single-arm study to demonstrate the efficacy
and safety of Privigen in the treatment of subjects with chronic inflammatory demyelinating
polyneuropathy (CIDP) (January 2011-July 2011, co-investigator).
- Phase II/III Trofos: Phase II/III, multicenter, randomized, parallel group, double-blind, placebo
controlled study to assess safety and efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS)
patients treated with riluzole (August 2009-December 2011, co-investigator).
- Phase I sNN0029 study with intracerebroventricular delivery of VEGF sponsored by Neuronova,
(December 2008-present, co-investigator).
- Phase III ALSTAR talampanel study (site 3709) sponsored by TEVA Pharma (September 20082010, co-investigator).
- Sigma Tau Study: Evaluation of Acetyl-L-carnitine (Protocol number ST200-DM-04-005, study center
number 24) to reduce intensity of Taxanes - or Platinum-induced sensory neuropathy (2006-2008, coinvestigator).
20/10/15
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 10 / 10